Market Insights Health Hospitals Inpatient Care

Treatment of Cardiovascular Diseases - EU-27

EU-27

In the EU-27, the Treatment of Cardiovascular Diseases market is anticipated to witness a significant growth in revenue, with projections indicating that it will reach US$84.06bn by the year 2024.
Moreover, it is expected that the market will continue to expand at a Compound Annual Growth Rate (CAGR) of 3.70% between 2024 and 2029, resulting in a market volume of US$100.80bn by 2029.
When compared to other countries globally, United States is expected to generate the highest revenue in this market, with an estimated amount of US$136.00bn in 2024.
In the EU-27, Germany has emerged as a leader in the development and adoption of innovative treatment options for cardiovascular diseases.

Key regions: Germany, France, Japan, Europe, India

Market

Region

Region comparison

Currency

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on revenue received by hospitals from public or private sources, allocated to the country where the money is spent, including VAT if applicable.

Modeling approach / Market size:

Market sizes are determined by a bottom-up approach, based on a specific rationale for each market market. Next, we use relevant key market indicators and data from country-specific associations, such as healthcare expenditure per capita, health risk factors, public health spend, and GDP. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level.